Follow Us
© 2026 Arizent. All rights reserved.
The Biden administration is seeking public comment on shortages of cancer treatments and other drugs related to the role that middlemen play in the pharmaceutical supply chain, the U.S. Federal Trade Commission said Wednesday.
In a joint request for information by the FTC and Department of Health and Human Services Wednesday, the federal government asked about shortages of generic drugs and whether groups that purchase quantities in bulk are contributing to the problem.
For reprint and licensing requests for this article, click here.
The plan to eventually phase out rebates portends a seismic shift in the flow of billions of dollars among drugmakers, insurers and employers.
When doctors, hospitals, insurers and brokers profit from lower costs and better outcomes, game-changing results will follow.
The increase in brand name drug access means the compounding drug industry will stop selling its copycat versions within the next few months.
Data shows a noticeable decline in obesity among those taking medications such as Ozempic and Zepbound.
New York is setting new rules to rein in prescription drug middlemen — including CVS Health and UnitedHealth Group.
